91 related articles for article (PubMed ID: 16165104)
1. Hypericum extract reverses S-ketamine-induced changes in auditory evoked potentials in humans - possible implications for the treatment of schizophrenia.
Murck H; Spitznagel H; Ploch M; Seibel K; Schaffler K
Biol Psychiatry; 2006 Mar; 59(5):440-5. PubMed ID: 16165104
[TBL] [Abstract][Full Text] [Related]
2. Effects of Hypericum extract (LI160) on the change of auditory evoked potentials by cortisol administration.
Murck H; Uhr M; Schaffler K; Seibel K
Neuropsychobiology; 2004; 50(2):128-33. PubMed ID: 15292666
[TBL] [Abstract][Full Text] [Related]
3. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
4. Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia.
D'Souza DC; Ahn K; Bhakta S; Elander J; Singh N; Nadim H; Jatlow P; Suckow RF; Pittman B; Ranganathan M
Biol Psychiatry; 2012 Nov; 72(9):785-94. PubMed ID: 22717030
[TBL] [Abstract][Full Text] [Related]
5. [Acoustic evoked potentials of medium latency. Anesthesia induction with S-(+)-ketamine versus ketamine racemate].
Schwender D; Faber-Züllig E; Fett W; Klasing S; Finsterer U; Peter K
Anaesthesist; 1993 May; 42(5):280-7. PubMed ID: 8317684
[TBL] [Abstract][Full Text] [Related]
6. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
Piskulić D; Olver JS; Maruff P; Norman TR
Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
[TBL] [Abstract][Full Text] [Related]
8. Ketamine effects on CNS responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man.
Boeijinga PH; Soufflet L; Santoro F; Luthringer R
J Psychopharmacol; 2007 May; 21(3):321-37. PubMed ID: 17591659
[TBL] [Abstract][Full Text] [Related]
9. Differentiating cortical patterns of cognitive dysfunction in schizophrenia and posttraumatic stress disorder.
Galletly CA; McFarlane AC; Clark R
Psychiatry Res; 2008 May; 159(1-2):196-206. PubMed ID: 18423610
[TBL] [Abstract][Full Text] [Related]
10. [Cognitive evoked potentials in patients with schizophrenia].
Chen X; Zhang M; Lou F
Zhonghua Yi Xue Za Zhi; 1999 Sep; 79(9):676-8. PubMed ID: 11715457
[TBL] [Abstract][Full Text] [Related]
11. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
[TBL] [Abstract][Full Text] [Related]
12. Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice.
Ehrlichman RS; Maxwell CR; Majumdar S; Siegel SJ
J Cogn Neurosci; 2008 Aug; 20(8):1403-14. PubMed ID: 18303985
[TBL] [Abstract][Full Text] [Related]
13. Acute and chronic effects of ketamine on semantic priming: modeling schizophrenia?
Stefanovic A; Brandner B; Klaassen E; Cregg R; Nagaratnam M; Bromley LM; Das RK; Rossell SL; Morgan CJ; Curran HV
J Clin Psychopharmacol; 2009 Apr; 29(2):124-33. PubMed ID: 19512973
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study.
Randløv C; Mehlsen J; Thomsen CF; Hedman C; von Fircks H; Winther K
Phytomedicine; 2006 Mar; 13(4):215-21. PubMed ID: 16423519
[TBL] [Abstract][Full Text] [Related]
15. Impact of modafinil on prefrontal executive function in schizophrenia.
Hunter MD; Ganesan V; Wilkinson ID; Spence SA
Am J Psychiatry; 2006 Dec; 163(12):2184-6. PubMed ID: 17151173
[TBL] [Abstract][Full Text] [Related]
16. Semantic priming after ketamine acutely in healthy volunteers and following chronic self-administration in substance users.
Morgan CJ; Rossell SL; Pepper F; Smart J; Blackburn J; Brandner B; Curran HV
Biol Psychiatry; 2006 Feb; 59(3):265-72. PubMed ID: 16140283
[TBL] [Abstract][Full Text] [Related]
17. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.
Krystal JH; Perry EB; Gueorguieva R; Belger A; Madonick SH; Abi-Dargham A; Cooper TB; Macdougall L; Abi-Saab W; D'Souza DC
Arch Gen Psychiatry; 2005 Sep; 62(9):985-94. PubMed ID: 16143730
[TBL] [Abstract][Full Text] [Related]
18. HT1001, a proprietary North American ginseng extract, improves working memory in schizophrenia: a double-blind, placebo-controlled study.
Chen EY; Hui CL
Phytother Res; 2012 Aug; 26(8):1166-72. PubMed ID: 22213250
[TBL] [Abstract][Full Text] [Related]
19. The effect of perospirone on auditory P300 in schizophrenia: a preliminary study.
Araki T; Kasai K; Rogers MA; Kato N; Iwanami A
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1083-90. PubMed ID: 16723179
[TBL] [Abstract][Full Text] [Related]
20. Ketamine produces lasting disruptions in encoding of sensory stimuli.
Maxwell CR; Ehrlichman RS; Liang Y; Trief D; Kanes SJ; Karp J; Siegel SJ
J Pharmacol Exp Ther; 2006 Jan; 316(1):315-24. PubMed ID: 16192313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
